Receptor TrK
Os inibidores dos receptores Trk têm como alvo as quinases receptoras da tropomiosina (Trk), uma família de tirosina quinases receptoras que desempenham um papel significativo no desenvolvimento e função do sistema nervoso. Os receptores Trk estão envolvidos na sinalização de neurotrofinas, essencial para a sobrevivência, diferenciação e crescimento dos neurônios. A desregulação da sinalização Trk está associada a distúrbios neurológicos e certos tipos de câncer. Na CymitQuimica, oferecemos inibidores dos receptores Trk para apoiar sua pesquisa em neurobiologia, oncologia e doenças neurodegenerativas.
Foram encontrados 59 produtos de "Receptor TrK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TrkA-IN-9
CAS:<p>TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.</p>Fórmula:C31H32N4O4Cor e Forma:SolidPeso molecular:524.61PF-06273340
CAS:<p>PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。</p>Fórmula:C23H22ClN7O3Pureza:98% - 98.00%Cor e Forma:SolidPeso molecular:479.92NMS-P626
CAS:<p>NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.</p>Fórmula:C28H35F2N7O4SCor e Forma:SolidPeso molecular:603.68BNN-20
CAS:<p>BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.</p>Fórmula:C20H30O2Cor e Forma:SolidPeso molecular:302.45TrkC-IN-1
CAS:<p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>Fórmula:C28H20BrN5O2Cor e Forma:SolidPeso molecular:538.395ONO-7579
CAS:<p>ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.</p>Fórmula:C24H18ClF3N6O4SCor e Forma:SolidPeso molecular:578.95HS-345
CAS:<p>HS-345, a TrkA/Akt inhibitor, exhibits potent anti-pancreatic cancer properties. This compound inhibits the growth and proliferation of pancreatic cancer cells by blocking the TrkA/Akt signaling pathway and induces cell apoptosis (Apoptosis). Additionally, HS-345 inhibits angiogenesis by reducing the expression of HIF-1α and VEGF. It holds promise for use in pancreatic cancer research.</p>Fórmula:C19H18N6O2SCor e Forma:SolidPeso molecular:394.45Trk-IN-4
CAS:<p>Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.</p>Fórmula:C24H23F4N5O4Pureza:98.13%Cor e Forma:SolidPeso molecular:521.46TrkB-IN-1
CAS:<p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>Fórmula:C19H16N2O6Pureza:98%Cor e Forma:SolidPeso molecular:368.34
